Clik here to view.
ITM and CIRC Sign Technology License Agreement for the Production and...
MUNICH & GARCHING, Germany ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and Chengdu Gaotong Isotope Co., Ltd. a subsidiary of China...
View ArticleClik here to view.
FDA Accepts Samsung Bioepis’ BLA for SB8 Bevacizumab Biosimilar Candidate
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) under the 351(k)...
View ArticleClik here to view.
EdiGene to Present Data on Manufacturing Scale-up and Preclinical Development...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery,...
View ArticleClik here to view.
Mevion Signs Agreement to Bring Proton Therapy to Central Taiwan
LITTLETON, Mass. Mevion Medical Systems today announced it had signed a collaborative framework agreement with Chung Shan Medical University Hospital and ASYS Corp to provide advanced proton therapy...
View ArticleClik here to view.
路胜生物完成由IHH Healthcare领投的2千万美元A轮投资，用于推动液体活检技术，进行多种癌症早期检测
新加坡 (美国商业资讯)– 路胜生物(Lucence)，发明用于癌症筛查, 治疗选择的血液检测的基因组医学公司，今天宣布完成2千万美元A轮融资。此轮融资的领投者是全球最大的综合私人医疗保健集团之一IHH Healthcare。参投者包括新加坡创新机构(SGInnovate)，以及现有投资者淡马锡控股(Temasek Holdings) 旗下的海丽凯资本管理公司(Heliconia...
View ArticleClik here to view.
Lucence Raises USD $20M Series A Led by IHH Healthcare to Advance Liquid...
SINGAPORE Lucence, a genomic medicine company that invents blood-based tests for cancer screening and treatment selection, announced today the close of USD $20 million in Series A funding. The round...
View ArticleClik here to view.
Asian Entrepreneurship Award 2019: Acumen Research Labs of Singapore Wins...
CHIBA, Japan The Asian Entrepreneurship Award Steering Committee announced today that Acumen Research Labs of Singapore won first prize at the Asian Entrepreneurship Awards 2019 (AEA 2019), a...
View ArticleClik here to view.
Phenomics Health Inc. 收购专利药物代谢组技术
密西根州安娜堡 (美国商业资讯)–基于生物信息学平台的精准医学公司Phenomics Health Inc.今天宣布，其已收购总部位于美国田纳西州富兰克林的Precera Bioscience公司的专利药物代谢组技术组合。 Phenomics Health计划将该新技术与自身的专利先进药物基因组平台相整合，在患者对用药的潜在和实际应答方面，向医疗保健提供者提供比现有技术更完整的图景。...
View ArticleClik here to view.
Zymeworks在ESMO亚洲大会上宣布推进与百济神州的临床合作并公布ZW25用于治疗HER2呈阳性癌症患者的1期临床研究更新数据
新加坡 (美国商业资讯)– Zymeworks Inc. (NYSE: ZYME)是一家处于临床开发阶段、专注于多功能治疗药物开发的生物制药公司。公司今天宣布在11月22 – 24日于新加坡召开的2019年ESMO 亚洲大会上，韩国首尔大学教授兼该研究的研究者Do-Youn...
View ArticleClik here to view.
Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and...
SINGAPORE Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated Phase 1 data for single agent ZW25 in heavily...
View ArticleClik here to view.
Phenomics Health Inc. Acquires Patented Pharmacometabolomic Technology
ANN ARBOR, Mich. Phenomics Health Inc., a bioinformatics platform-based precision medicine company, today announced it has acquired the patented pharmacometabolomic technology portfolio of Precera...
View ArticleClik here to view.
Takeda Presents Long-Term Data in ALK+ NSCLC Showing ALUNBRIG® (brigatinib)...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced updated data from the Phase 3 ALTA-1L trial, which evaluated ALUNBRIG versus crizotinib...
View ArticleClik here to view.
Delta-Fly Pharma, Inc. Initiated Phase 3 Clinical Study of DFP-10917 and...
TOKUSHIMA, Japan Delta-Fly Pharma, Inc. (TOKYO: 4598) announces that patients have registered for clinical studies in the USA on anti-cancer drug candidates DFP-10917 and DFP-14927. DFP-10917 is an...
View ArticleClik here to view.
武田呈报的ALK+ NSCLC长期数据显示，ALUNBRIG® (brigatinib)在2年随访期之后继续展示一线治疗中的优效性
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE:4502/NYSE:TAK)今天发布了3期ALTA-1L试验的更新数据，该试验评估ALUNBRIG...
View ArticleClik here to view.
Genetron Health Obtains Approval for Semiconductor-based NGS System GENETRON S5
BEIJING Genetron Health, a China-based precision oncology company that covers full-cycle cancer care, has obtained regulatory approval in China to launch its GENETRON S5 for clinical use. The...
View ArticleClik here to view.
武田薬品、ALK+ NSCLC のファーストライン治療でALUNBRIG®（ブリガチニブ）が2年間の追跡後も一貫した優位性を示す長期データを発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） —...
View ArticleClik here to view.
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with...
BOTHELL, Wash. & TOKYO Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), today announced a clinical collaboration...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Bortezomib for Injection 3.5...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the...
View ArticleClik here to view.
OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised...
SAN DIEGO & PENNINGTON, N.J. OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, issued a statement...
View ArticleClik here to view.
LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in...
KENILWORTH, N.J. AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the companies have received marketing authorization from China’s National...
View Article